Brought to you by 
Boehringer Ingelheim buys heartburn drug Zantac for $509.5mm
02 Nov 2006
Executive Summary
As Johnson & Johnson continues to divest products to pave the way for its acquisition of Pfizer Consumer Health Care Group, the company and Pfizer have agreed to sell all US rights, title, and interest in Pfizer's OTC anti-ulcerant Zantac (ranitidine) to Boehringer Ingelheim Pharmaceuticals for $509.5mm in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer Ingelheim buys heartburn drug Zantac for $509.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice